Evaluation of a 2-pyridone, KRQ-10018, against Mycobacterium tuberculosis in vitro and in vivo.

Abstract

A novel subclass of quinolones, 2-pyridones, showed potent activity against Mycobacterium tuberculosis, with KRQ-10018 being an early lead. KRQ-10018 showed better activity in vitro against M. tuberculosis versus moxifloxacin. In vivo efficacy of KRQ-10018 at 300 mg/kg of body weight was similar to that of isoniazid at 25 mg/kg, but showed less activity than moxifloxacin at 300 mg/kg.

DOI: 10.1128/AAC.00897-07

Cite this paper

@article{Lenaerts2008EvaluationOA, title={Evaluation of a 2-pyridone, KRQ-10018, against Mycobacterium tuberculosis in vitro and in vivo.}, author={Anne J M Lenaerts and Casey P Bitting and Lisa K. Woolhiser and Veronica Gruppo and Karen S Marietta and Christine M. Johnson and I . M . Orme}, journal={Antimicrobial agents and chemotherapy}, year={2008}, volume={52 4}, pages={1513-5} }